Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (15857)	2/23/2005 4:52:23 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 52153

Mike, Couldn't agree more about Robinson! This guy has missed projections more times than the Chicago Cubs have missed making it to the World Series. However, in listening to his presentation today he all but said that they will be profitable this previous Q(not based on actual product sales probably). At the current price levels and with the "great" potential that Targretin could become a top-line treatment for lung cancer, I've started adding a few shares. I bought yesterday at the $9.60 level and added more today at these levels as IMO it is worth the gamble as we will know the results within weeks on Targretin. Fingers crossed and with Mapquest handy to located Robinson...I think the future is finally here for LGND. It has been a long slog!